AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 27023447
Drug: TSH ≥
RxNorm normalized name: Thyroid Stimulating Hormone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TSH ≥ 2.5 mIU/L
Trial: 27023447
Drug: TSH <
RxNorm normalized name: Thyroid Stimulating Hormone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TSH < 2.5 mIU/L
Trial: 7724385
Drug: Epicardial patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epicardial patch (EPI)
Trial: 23184900
Drug: 50,000 IU
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50,000 IU of oral ergocalciferol weekly for 12 weeks
Trial: 19914548
Drug: Sequential treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential treatment arms
Trial: 18184078
Drug: ddI +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ddI + 1000 mg HU
Trial: 18184078
Drug: ddI +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ddI + 1500 mg HU
Trial: 18184078
Drug: HU monotherapy
RxNorm normalized name: Hu-PHEC Liver
DrugBank: Hu-PHEC Liver (DB18347)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HU monotherapy
Trial: 15700852
Drug: Gemcitabine (1,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine (1,000 mg/m2 intravenously weekly for 7 weeks, followed by 1 week of rest, then weekly for 3 weeks every 4 weeks)
Trial: 15700852
Drug: FLEC (5-fluorouracil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FLEC (5-fluorouracil 1,000 mg/m2, leucovorin 100 mg/m2, epirubicin 60 mg/m2, carboplatin 300 mg/m2 infused intra-arterially at a 3-week interval 3 times or 5-fluorouracil 400 mg/m2 plus folinic acid 20 mg/m2 for 5 days every 4 weeks for 6 cycles)
Trial: 11240079
Drug: Behavior-oriented physical
RxNorm normalized name: Oriental melon
DrugBank: Muskmelon (DB15611)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavior-oriented physical therapy (PT)
Trial: 9855165
Drug: Weight loss
RxNorm normalized name: HERBAL WEIGHT LOSS AID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weight loss and treatment with acetazolamide during a 24‐week period
Trial: 8642232
Drug: Metoprolol (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol (5 mg)
Trial: 2728087
Drug: Bayesian dosing
RxNorm normalized name: Babesia microti preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bayesian dosing program for phenytoin
Trial: 4157355
Drug: Aqueous procaine
RxNorm normalized name: Aqueous procaine penicillin G
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aqueous procaine penicillin G (2,400,000 U for men; 2,400,000 U daily for 2 days for women)
Trial: 4157355
Drug: Spectinomycin hydrochloride
RxNorm normalized name: Spectinomycin Hydrochloride
DrugBank: Spectinomycin (DB00919)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Spectinomycin hydrochloride (2.0 g for men; 4.0 g for women)
Trial: 25554757
Drug: Pilot intervention
RxNorm normalized name: Picot
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pilot intervention (immunization records obtained, immunization status determined, catch-up doses administered before discharge)
Trial: 16505498
Drug: Benfluorex 450
RxNorm normalized name: benfluorex
DrugBank: Benfluorex (DB09022)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benfluorex 450 mg/day
Trial: 7990479
Drug: Oral Ftorafur
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Ftorafur (10 mg/kg daily)
Trial: 7990479
Drug: Oral Ftorafur
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Ftorafur
Trial: 31104111
Drug: Desensitizing gel
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Desensitizing gel applied for 10 min before bleaching with 35% hydrogen peroxide, followed by placebo gel after.
Trial: 31104111
Drug: Desensitizing gel
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Desensitizing gel applied for 10 min before and after bleaching procedure.
Trial: 31104111
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (desensitizing gel before and before & after)
Trial: 22013799
Drug: Benzbromarone Tablet
RxNorm normalized name: benzbromarone
DrugBank: Benzbromarone (DB12319)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benzbromarone Tablet (50 mg, once per day)
Trial: 8557066
Drug: rhIGF‐I (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhIGF‐I (80 micrograms kg‐1 bw) subcutaneously twice daily
Trial: 8557066
Drug: IGF‐I (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IGF‐I (1 microgram mL‐1) in vitro
Trial: 2172885
Drug: Megestrol acetate
RxNorm normalized name: Megestrol Acetate
DrugBank: Megestrol (DB19378)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Megestrol acetate at a dose of 160 mg/day
Trial: 2172885
Drug: Megestrol acetate
RxNorm normalized name: Megestrol Acetate
DrugBank: Megestrol (DB19378)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Megestrol acetate at a dose of 480 mg/day
Trial: 25072441
Drug: Nonoperative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonoperative treatment with antibiotics
Trial: 28279659
Drug: Usual treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual treatment (1 session a day)
Trial: 17240120
Drug: Escitalopram (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escitalopram (10 mg or 20 mg)
Trial: 15524059
Drug: Atorvastatin 10-40
RxNorm normalized name: atorvastatin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 10-40 mg daily
Trial: 15524059
Drug: Atorvastatin 20
RxNorm normalized name: atorvastatin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 20 and 40 mg daily
Trial: 7930780
Drug: Intravenous secretin
RxNorm normalized name: Secretin
DrugBank: Secretin human (DB09532)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous secretin injection
Trial: 30358724
Drug: Estrogen plus
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estrogen plus progestogen therapy (EPT) - 0.625 mg conjugated equine estrogens plus 2.5 mg medroxyprogesterone acetate
Trial: 19571077
Drug: 0.75% ropivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.75% ropivacaine infusion at 5 mL/hr
Trial: 19571077
Drug: 0.75% ropivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.75% ropivacaine infusion
Trial: 19571077
Drug: 0.75% ropivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.75% ropivacaine infusion and Placebo
Trial: 16624769
Drug: Vitamin B12
RxNorm normalized name: Vitamin B12
DrugBank: Cyanocobalamin Co-57 (DB09385)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin B12 mixed solution inhalation
Trial: 16624769
Drug: Gentamycin sulfate
RxNorm normalized name: Gentamicin Sulfate 3 MG/1 ML Ophthalmic Solution [GENTAMYCIN SULFATE]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gentamycin sulfate mixed solution inhalation
Trial: 8277057
Drug: Luting agents
RxNorm normalized name: Solvents and diluting agents, incl. irrigating solutions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Luting agents with resin restorative systems
Trial: 8277057
Drug: Luting agents
RxNorm normalized name: Solvents and diluting agents, incl. irrigating solutions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Luting agents with ceramic restorative systems
Trial: 20572863
Drug: Changes in
RxNorm normalized name: guaifenesin / hydrocodone bitartrate Oral Solution [Canges XP]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Changes in knowledge and attitudes related to oral health
Trial: 10326791
Drug: fenretinide (4‐HPR)
RxNorm normalized name: FENRETINIDE
DrugBank: Fenretinide (DB05076)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: fenretinide (4‐HPR) administered for a mean of 40 months
Trial: 26337944
Drug: High-dose ranibizumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose ranibizumab (1.0/0.1 ml or 2.0 mg/0.05 ml; n=15)
Trial: 26337944
Drug: Standard-dose ranibizumab
RxNorm normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Standard-dose ranibizumab (0.5 mg/0.05 ml; n=5)
Trial: 11165993
Drug: Misoprostol in
RxNorm normalized name: Product containing misoprostol in oral dose form (medicinal product form)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Misoprostol in combination with NSAID
Trial: 9432097
Drug: Terbutaline (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terbutaline (3 mg from MDI)
Trial: 3690029
Drug: Almitrine bismesylate
RxNorm normalized name: almitrine dimesylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Almitrine bismesylate therapy
Trial: 23795326
Drug: Preoperative patient
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative patient education (oral and written)
Trial: 2678885
Drug: Savlon as
RxNorm normalized name: Savlon Dry
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Savlon as a cleansing agent before ocular surgery
Trial: 4855182
Drug: Treatment prognosis
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment prognosis ratings by therapists
Trial: 25858909
Drug: Ciclesonide 320
RxNorm normalized name: Ciclesonide
DrugBank: Ciclesonide (DB01410)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ciclesonide 320 µg twice daily
Trial: 25858909
Drug: Ciclesonide 320
RxNorm normalized name: Ciclesonide
DrugBank: Ciclesonide (DB01410)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ciclesonide 320 µg twice daily (excluding patients who changed prednisolone dose)
Trial: 11211366
Drug: Methylphenidate (MPH)
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylphenidate (MPH) - doses: placebo, low, middle, high
Trial: 11211366
Drug: Methylphenidate (MPH)
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylphenidate (MPH) - total daily dose limit of 35 mg for children weighing less than 25 kg
Trial: 9644316
Drug: Weekly chemotherapy
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly chemotherapy (Arm B): CDDP (40 mg/m2), VDS (3 mg/m2), MMC (4 mg/m2) on day 1, followed by CDDP (20 mg/m2), VDS (1.5 mg/m2), MMC (2 mg/m2) weekly.
Trial: 9644316
Drug: Monthly chemotherapy
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Monthly chemotherapy (Arm A): CDDP (80 mg/m2) monthly on day 1, VDS (3 mg/m2) on days 1 and 8, MMC (8 mg/m2) on day 1.
Trial: 31564829
Drug: New generic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New generic formulation of S-1
Trial: 31564829
Drug: Branded reference
RxNorm normalized name: Eagle Brand Medicated Oil
DrugBank: Eucalyptus oil (DB11114)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Branded reference formulation of S-1
Trial: 22925226
Drug: Levetiracetam (LEV)
RxNorm normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Levetiracetam (LEV) at a maximum dose of 3000 mg
Trial: 16945231
Drug: Diazepam administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam administered
Trial: 16945231
Drug: Midazolam administered
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Midazolam administered
Trial: 16945231
Drug: Placebo with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo with saline administration
Trial: 10356916
Drug: Metabolic complex
RxNorm normalized name: hesperidin complex
DrugBank: Citrus bioflavonoids (DB14586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metabolic complex of amino acids (100 mg 3 times a day for 20 days)
Trial: 8568118
Drug: Acetate alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetate alone (56.25 mmol/L)
Trial: 8568118
Drug: Acetate plus
RxNorm normalized name: prednisolone acetate Ophthalmic Suspension [Econopred Plus]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetate plus propionate (56.25 mmol/L + 18.75 mmol/L)
Trial: 8568118
Drug: Acetate plus
RxNorm normalized name: prednisolone acetate Ophthalmic Suspension [Econopred Plus]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetate plus calcium (56.25 mmol/L + 50 mmol/L)
Trial: 8568118
Drug: Acetate, propionate,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetate, propionate, and calcium together (56.25 mmol/L + 18.75 mmol/L + 50 mmol/L)
Trial: 8568118
Drug: Propionate alone
RxNorm normalized name: propionate
DrugBank: Propionate ion (DB19384)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propionate alone (18.75 mmol/L)
Trial: 1836088
Drug: lynestrenol 5-10
RxNorm normalized name: lynestrenol
DrugBank: Lynestrenol (DB12474)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lynestrenol 5-10 mg
Trial: 1836088
Drug: DMPA (intramuscular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DMPA (intramuscular administration)
Trial: 7058319
Drug: bezafibrate (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bezafibrate (3 X 200 mg daily)
Trial: 7058319
Drug: colestipol (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: colestipol (2 X 10 g per day)
Trial: 7058319
Drug: probucol (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: probucol (2 X 500 mg daily)
Trial: 7058319
Drug: dietary treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dietary treatment alone
Trial: 27276431
Drug: Formula containing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formula containing 25 mg ARA/100 kcal
Trial: 27276431
Drug: Formula containing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formula containing 34 mg ARA/100 kcal
Trial: 27276431
Drug: Formula containing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formula containing 0 mg ARA/100 kcal
Trial: 21517195
Drug: Interaction between
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interaction between DD and treatment condition
Trial: 16867025
Drug: Zolpidem modified-release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zolpidem modified-release (MR) 12.5 mg
Trial: 16867025
Drug: Zolpidem immediate-release
RxNorm normalized name: zolpidem Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zolpidem immediate-release (IR) 10 mg
Trial: 16867025
Drug: Zolpidem intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zolpidem intravenous (i.v.) infusion 8 mg
Trial: 1354275
Drug: Fluorouracil (1
RxNorm normalized name: Fluorouracil (18-F)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluorouracil (1 g per day) plus heparin (10,000 U per day) during and after surgery for 7 days
Trial: 6352304
Drug: Inhaled beta-2-agonists
RxNorm normalized name: 2-HYDROXYPROPYL-BETA-CYCLODEXTRIN
DrugBank: Hydroxypropyl betadex (DB15379)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled beta-2-agonists (2.5 mg terbutaline)
Trial: 6352304
Drug: Intramuscular dosed
RxNorm normalized name: intramuscular immunoglobulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular dosed beta-2-agonists (1/4 mg terbutaline)
Trial: 30650256
Drug: Topical GSK1940029
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical GSK1940029 (0.3% and 1%, occluded application)
Trial: 30650256
Drug: Topical GSK1940029
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical GSK1940029 (0.1% to 1%, single and repeat doses, occluded and nonoccluded applications)
Trial: 30650256
Drug: Topical GSK1940029
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical GSK1940029 (0.1% to 1%, occluded application)
Trial: 8829954
Drug: Lipid-lowering drugs
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipid-lowering drugs and diet (2 to 3 years)
Trial: 346140
Drug: Bulk forming
RxNorm normalized name: Bulk forming laxative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bulk forming agent (ispaghula husk)
Trial: 31345179
Drug: APAD intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: APAD intervention (thrice-weekly moderate-intensity mixed aerobic and resistance exercise sessions and 9 dietetic consultations)
Trial: 29059644
Drug: Resveratrol at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resveratrol at a dose of 100 mg per os daily added to standard therapy
Trial: 29059644
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy (Β‐blockers, statins, aspirin)
Trial: 15513305
Drug: Amlodipine-based antihypertensive
RxNorm normalized name: Amlodipine free base
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amlodipine-based antihypertensive therapy
Trial: 11757505
Drug: Folate treatment
RxNorm normalized name: folate
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folate treatment (1 mg folic acid, 400 microg vitamin B12, 10 mg pyridoxine)
Trial: 11757505
Drug: Folate treatment
RxNorm normalized name: folate
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folate treatment
Trial: 3003206
Drug: Acyclovir (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acyclovir (10 mg/kg) administered intravenously at 8-hr intervals for seven days
Trial: 3003206
Drug: Acyclovir (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acyclovir (10 mg/kg)
Trial: 31330457
Drug: Multiple-injection paravertebral
RxNorm normalized name: sodium acetate
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Multiple-injection paravertebral block (PVB)
Trial: 31330457
Drug: Single-injection erector
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-injection erector spinae plane block (ESPB)
Trial: 10073741
Drug: xamoterol (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: xamoterol (2 x 200 mg day(‐1) p.o.)
Trial: 10073741
Drug: xamoterol (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: xamoterol (2 x 200 mg day(‐1) p.o.) after 2 weeks
Trial: 10073741
Drug: ketotifen (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ketotifen (2 x 1 mg day(‐1) p.o.)
Trial: 7030976
Drug: Proxyphylline (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proxyphylline (500 mg orally three times daily) + Salbutamol (3 mg p.o.)
Trial: 7030976
Drug: Proxyphylline (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proxyphylline (500 mg orally three times daily) + Placebo
Trial: 31994510
Drug: Migrepam (zolmitriptan)
RxNorm normalized name: Zolmitriptan
DrugBank: Zolmitriptan (DB00315)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Migrepam (zolmitriptan) 2.5 mg
Trial: 26785820
Drug: Quercetin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quercetin (500 mg daily for 4 weeks)
Trial: 19029269
Drug: Autologous platelet
RxNorm normalized name: AUTOLOGOUS PLATELET RICH PLASMA
DrugBank: Platelet Rich Plasma (DB19295)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous platelet gel (APG)
Trial: 20605484
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (standard surgical treatment without APG)
Trial: 15957842
Drug: Jinye Baidu
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Jinye Baidu granule (JBG) combined with zinc gluconate tablet at a dose of 30 mg daily
Trial: 15957842
Drug: Jinye Baidu
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Jinye Baidu granule (JBG) combined with zinc gluconate tablet at a dose of 20 mg daily
Trial: 15957842
Drug: Jinye Baidu
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Jinye Baidu granule (JBG) combined with zinc gluconate tablet at a dose of 10 mg daily
Trial: 10091737
Drug: Adjuvant CMF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant CMF chemotherapy (6 courses)
Trial: 10091737
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no systemic adjuvant treatment)
Trial: 7751496
Drug: Relaxation-biofeedback training
RxNorm normalized name: endothelium-derived relaxing factor
DrugBank: Nitric Oxide (DB00435)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Relaxation-biofeedback training with propranolol (60, 120, or 180 mg/day)
Trial: 31648072
Drug: Cookstove treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cookstove treatments
Trial: 30057406
Drug: Trabectedin 1.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trabectedin 1.3 mg/m2
Trial: 30057406
Drug: Gemcitabine 900
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine 900 mg/m2 and docetaxel 75 mg/m2
Trial: 27502725
Drug: Bevacizumab plus
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab plus second-line chemotherapy
Trial: 18063879
Drug: Gemtuzumab ozogamicin
RxNorm normalized name: Gemtuzumab Ozogamicin
DrugBank: Gemtuzumab ozogamicin (DB00056)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Gemtuzumab ozogamicin (GO) 6 mg/m2 and standard-dose cytarabine 100 mg/m2
Trial: 18063879
Drug: Gemtuzumab ozogamicin
RxNorm normalized name: Gemtuzumab Ozogamicin
DrugBank: Gemtuzumab ozogamicin (DB00056)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Gemtuzumab ozogamicin (GO) 3 mg/m2 with standard- and high-dose cytarabine and anthracyclines
Trial: 18063879
Drug: Gemtuzumab ozogamicin
RxNorm normalized name: Gemtuzumab Ozogamicin
DrugBank: Gemtuzumab ozogamicin (DB00056)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Gemtuzumab ozogamicin (GO) 3 mg/m2 and high-dose cytarabine 3 g/m2
Trial: 30361792
Drug: Ultramicronized palmitoylethanolamide
RxNorm normalized name: Palmitoylethanolamide
DrugBank: Palmidrol (DB14043)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultramicronized palmitoylethanolamide 600 mg twice daily for 60 days
Trial: 18765504
Drug: Warfarin exposure
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin exposure (1-month time window)
Trial: 18765504
Drug: Warfarin exposure
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin exposure (1 to 3 prescriptions in the previous year)